Literature DB >> 9115153

Bone modeling indexes at onset and during the first year of follow-Up in insulin-dependent diabetic children.

R Bonfanti1, S Mora, C Prinster, E Bognetti, F Meschi, M Puzzovio, M C Proverbio, G Chiumello.   

Abstract

Osteopenia has been described as a complication of insulin-dependent diabetes mellitus (IDDM). We measured bone modeling indexes during the first year of IDDM. At each time point the values obtained from diabetic children have been compared with those of control subjects. We selected 27 prepubertal children with IDDM (6.35 +/- 2.16 years). We also enrolled 30 healthy prepubertal children of comparable age (5.85 +/- 3.05 years). Height, height standard deviation scores, glycated haemoglobin (HbA1C), basal c-peptide concentrations, insulin dose, serum concentrations of procollagen type I C-terminal propeptide (PICP), and collagen type I C-terminal telopeptide (ICTP) were measured at onset of IDDM and at 3, 6 and 12 months. ICTP was in the normal range at onset of IDDM and decreased during the follow-up to reach a significant difference compared to controls after 3, 6 and 12 months of insulin treatment (P < 0.04). PICP concentrations increased significantly at 3 months (P = 0.05) compared to onset. At 3 and 12 months PICP values were significantly higher than those of control children (P = 0.04). Correlations were found between PICP concentrations and HbA1C and c-peptide at onset of diabetes (r = -0.45 and r = 0.47, respectively). Bone formation at onset of IDDM is not impaired; the introduction of insulin therapy, together with the achievement of a good metabolic control, determines an increase of bone matrix formation coupled with a decrease of bone resorption, that determines a positive balance of bone modeling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9115153     DOI: 10.1007/s002239900251

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  7 in total

Review 1.  Osteoporosis and diabetes mellitus.

Authors:  Angela M Inzerillo; Solomon Epstein
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

Review 3.  Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.

Authors:  Kathryn M Thrailkill; Charles K Lumpkin; R Clay Bunn; Stephen F Kemp; John L Fowlkes
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11       Impact factor: 4.310

4.  Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers.

Authors:  M T Saha; H Sievänen; M K Salo; S Tulokas; H H Saha
Journal:  Osteoporos Int       Date:  2008-12-13       Impact factor: 4.507

5.  CTX Correlation to Disease Duration and Adiponectin in Egyptian Children with T1DM.

Authors:  Amel A Hashim; Sahar A Ali; Ibrahim A Emara; Mohamed H El-Hefnawy
Journal:  J Med Biochem       Date:  2015-12-30       Impact factor: 3.402

6.  Streptozotocin, type I diabetes severity and bone.

Authors:  Katherine Motyl; Laura R McCabe
Journal:  Biol Proced Online       Date:  2009-03-06       Impact factor: 3.244

7.  IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes.

Authors:  Laurie J Moyer-Mileur; Hillarie Slater; Kristine C Jordan; Mary A Murray
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.